Massachusetts Financial Services CO Tricida, Inc. Transaction History

Massachusetts Financial Services CO

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 12, 2021	SELL	$4.37 - $9.46 $1.61 Million - $3.49 Million	-368,944 Closed	0 $0
Q3 2020 Nov 12, 2020	SELL	$8.56 - $26.93 $77,570 - $244,039	-9,062 Reduced 2.4%	368,944 $3.34 Million
Q2 2020 Aug 11, 2020	BUY	$21.21 - $31.55 $608,281 - $904,822	28,679 Added 8.21%	378,006 $10.4 Million
Q1 2020 May 14, 2020	BUY	$18.43 - $38.04 $630,748 - $1.3 Million	34,224 Added 10.86%	349,327 $7.69 Million
Q4 2019 Feb 13, 2020	BUY	$29.6 - $43.71 $2,841 - $4,196	96 Added 0.03%	315,103 $11.9 Million

Q3 2019 Nov 05, 2019	SELL	$29.87 - $42.22 $34,798 - $49,186	-1,165 Reduced 0.37%	315,007 $9.72 Million
Q2 2019 Aug 14, 2019	BUY	$31.16 - $39.46 $1.52 Million - $1.92 Million	48,686 Added 18.2%	316,172 $12.5 Million
Q1 2019 May 13, 2019	BUY	$19.96 - $38.62 $1.24 Million - $2.4 Million	62,077 Added 30.22%	267,486 $10.3 Million
Q4 2018 Feb 08, 2019	BUY	$23.57 - $32.33 $99,913 - $137,046	4,239 Added 2.11%	205,409 $4.84 Million
Q3 2018 Oct 25, 2018	SELL	$22.5 - $39.35 $675 - $1,180	-30 Reduced 0.01%	201,170 $6.15 Million
Q2 2018 Jul 30, 2018	BUY	$26.0 - $29.9 $5.23 Million - $6.02 Million	201,200 New	201,200 $6.02 Million

30K

124K

46.5K

Ticker TCDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,668,900
Market Cap $557K
Description
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...

Get notified when there are updates to the investment portfolio of Massachusetts Financial Services CO , based on Form 13F filings with the SEC.

Stay updated on Massachusetts Financial Services CO with notifications on news.